BURLINGTON, Mass., May 21, 2020 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share. The gross proceeds from this offering are expected to be approximately $90.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Flexion. The offering is expected to close on or about May 26, 2020, subject to customary closing conditions. Flexion has also granted the underwriters a 30-day option to purchase up to 1,384,615 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Goldman Sachs & Co. LLC and Credit Suisse are acting as joint book-running managers for the offering. RBC Capital Markets is acting as senior manager and Raymond James and Needham & Company are acting as co-managers for the offering.The shares of common stock described above are being offered pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement relating to the offering will be filed with the SEC and available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: Goldman Sachs & Co. LLC by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, 3rd Floor, New York, NY 10010, by telephone at (800) 221-1037, or by email at [email protected].This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Flexion TherapeuticsFlexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The company’s core values are focus, ingenuity, tenacity, transparency and fun.Forward-Looking StatementsContact:Scott Young
Vice President, Corporate Communications & Investor Relations
T: 781-305-7194
[email protected]Julie Downs
Associate Director, Corporate Communications & Investor Relations
T: 781-305-7137
[email protected]
Bay Street News